IL158041A0 - Benzimidazole derivatives and pharmaceutical compositions containing the same - Google Patents
Benzimidazole derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL158041A0 IL158041A0 IL15804102A IL15804102A IL158041A0 IL 158041 A0 IL158041 A0 IL 158041A0 IL 15804102 A IL15804102 A IL 15804102A IL 15804102 A IL15804102 A IL 15804102A IL 158041 A0 IL158041 A0 IL 158041A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- benzimidazole derivatives
- benzimidazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27932701P | 2001-03-28 | 2001-03-28 | |
PCT/US2002/009402 WO2002079192A1 (en) | 2001-03-28 | 2002-03-26 | Novel tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158041A0 true IL158041A0 (en) | 2004-03-28 |
Family
ID=23068491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15804102A IL158041A0 (en) | 2001-03-28 | 2002-03-26 | Benzimidazole derivatives and pharmaceutical compositions containing the same |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1381598A4 (en) |
JP (1) | JP2004534010A (en) |
KR (1) | KR20030083016A (en) |
CN (1) | CN1514833A (en) |
AR (1) | AR035804A1 (en) |
BG (1) | BG108206A (en) |
BR (1) | BR0208373A (en) |
CA (1) | CA2442428A1 (en) |
CZ (1) | CZ20032615A3 (en) |
EE (1) | EE200300475A (en) |
GE (1) | GEP20053660B (en) |
HR (1) | HRP20030844A2 (en) |
HU (1) | HUP0400323A2 (en) |
IL (1) | IL158041A0 (en) |
IS (1) | IS6968A (en) |
MX (1) | MXPA03008690A (en) |
NO (1) | NO20034308L (en) |
PE (1) | PE20021015A1 (en) |
PL (1) | PL373300A1 (en) |
RU (1) | RU2003131693A (en) |
SK (1) | SK12002003A3 (en) |
UY (1) | UY27234A1 (en) |
WO (1) | WO2002079192A1 (en) |
YU (1) | YU84603A (en) |
ZA (1) | ZA200307466B (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
AU2003218236B2 (en) | 2002-03-01 | 2007-12-06 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
AU2003243497A1 (en) * | 2002-06-12 | 2003-12-31 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
WO2004050033A2 (en) * | 2002-12-02 | 2004-06-17 | Arqule, Inc. | Method of treating cancers |
EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
WO2004069160A2 (en) * | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
DE102004010207A1 (en) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer |
AP2139A (en) | 2004-04-02 | 2010-08-21 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. |
US8101770B2 (en) * | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
US7393667B2 (en) | 2005-05-31 | 2008-07-01 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
AU2006278396A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CA2620352A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
EP1919891B1 (en) * | 2005-08-29 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
WO2007026720A1 (en) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Ring-fused pyrazole derivative |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007145203A1 (en) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | Optically active 2-amino-1-(4-fluorophenyl)ethanol |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
US8492328B2 (en) | 2007-05-17 | 2013-07-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CN101687840A (en) | 2007-06-25 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | Benzimidazole amido derivatives as kinase inhibitors |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
CA2712959C (en) | 2008-01-22 | 2015-06-23 | Vernalis (R & D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
WO2009143051A1 (en) | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
PE20120057A1 (en) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | SIRTUINE MODULATING THIAZOLOPYRIDINE COMPOUNDS |
DE102010001064A1 (en) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use |
JP2012524119A (en) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Preparation of C-pyrazine-methylamine |
US8536180B2 (en) * | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
KR101594002B1 (en) * | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Benzimidazole derivatives as pi3 kinase inhibitors |
JP5789888B2 (en) * | 2010-11-01 | 2015-10-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzimidazole inhibitors of leukotriene formation |
EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
KR102307566B1 (en) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | Novel bicyclic bromodomain inhibitors |
CN105492439B (en) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | Substituted dicyclic compound as bromine structural domain inhibitor |
WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
CN103936719A (en) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | Preparation method and application of benzimidazoles derivatives |
CN108064274A (en) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | For cultivating the culture medium of multipotential stem cell |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CN107207474B (en) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10179777B2 (en) * | 2015-04-16 | 2019-01-15 | Merck Patent Gmbh | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
CN117069696B (en) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | Double-target small molecule inhibitor and preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
SI1194425T1 (en) * | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituted benzimidazole |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
-
2002
- 2002-03-26 CA CA002442428A patent/CA2442428A1/en not_active Abandoned
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/en unknown
- 2002-03-26 PL PL02373300A patent/PL373300A1/en not_active Application Discontinuation
- 2002-03-26 EE EEP200300475A patent/EE200300475A/en unknown
- 2002-03-26 YU YU84603A patent/YU84603A/en unknown
- 2002-03-26 CN CNA028105168A patent/CN1514833A/en active Pending
- 2002-03-26 SK SK12002003A patent/SK12002003A3/en not_active Application Discontinuation
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/en not_active IP Right Cessation
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/en not_active Withdrawn
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/en active Application Filing
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/en unknown
- 2002-03-26 EP EP02723631A patent/EP1381598A4/en not_active Withdrawn
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/en not_active Application Discontinuation
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/en unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/en not_active Application Discontinuation
- 2002-03-26 IL IL15804102A patent/IL158041A0/en unknown
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/en not_active Application Discontinuation
- 2002-03-27 UY UY27234A patent/UY27234A1/en not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/en not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 BG BG108206A patent/BG108206A/en unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/en not_active Application Discontinuation
- 2003-09-26 IS IS6968A patent/IS6968A/en unknown
- 2003-10-17 HR HR20030844A patent/HRP20030844A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0208373A (en) | 2005-02-22 |
SK12002003A3 (en) | 2004-10-05 |
EP1381598A4 (en) | 2008-03-19 |
MXPA03008690A (en) | 2003-12-12 |
YU84603A (en) | 2006-03-03 |
CZ20032615A3 (en) | 2004-03-17 |
RU2003131693A (en) | 2005-05-10 |
UY27234A1 (en) | 2002-10-31 |
HUP0400323A2 (en) | 2005-11-28 |
CN1514833A (en) | 2004-07-21 |
EP1381598A1 (en) | 2004-01-21 |
IS6968A (en) | 2003-09-26 |
AR035804A1 (en) | 2004-07-14 |
WO2002079192A1 (en) | 2002-10-10 |
JP2004534010A (en) | 2004-11-11 |
NO20034308L (en) | 2003-11-26 |
GEP20053660B (en) | 2005-11-10 |
BG108206A (en) | 2004-11-30 |
KR20030083016A (en) | 2003-10-23 |
CA2442428A1 (en) | 2002-10-10 |
NO20034308D0 (en) | 2003-09-26 |
ZA200307466B (en) | 2005-01-13 |
HRP20030844A2 (en) | 2005-08-31 |
EE200300475A (en) | 2004-02-16 |
PL373300A1 (en) | 2005-08-22 |
PE20021015A1 (en) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158041A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
IL161616A0 (en) | Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
IL158044A0 (en) | Cyclopropylindole derivatives and pharmaceutical compositions containing the same | |
IL158300A0 (en) | Bisarylimidazol derivatives and pharmaceutical compositions containing the same | |
IL175252A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
IL162548A0 (en) | 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same | |
IL166482A0 (en) | Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same | |
IL158076A0 (en) | Benzamidine derivatives and pharmaceutical compositions containing the same | |
IL163117A (en) | Indazole derivatives and pharmaceutical compositions containing the same | |
IL159725A0 (en) | Pharmaceutical compositions containing benzimidazole derivatives | |
IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
IL156812A0 (en) | Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same | |
IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
IL158523A0 (en) | Epothilone derivatives and pharmaceutical compositions containing the same | |
IL157131A0 (en) | Nitrogen containing heterocyclic derivatives and pharmaceutical compositions containing the same | |
IL164209A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL166620A0 (en) | Pyrazole derivatives and pharmaceutical compositions containing the same | |
IL173602A0 (en) | Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same | |
IL173627A0 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same | |
HUP0400467A3 (en) | 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use | |
IL173051A0 (en) | N-glucoside derivatives and pharmaceutical compositions containing the same | |
IL171997A0 (en) | Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same | |
IL155196A0 (en) | Benzamide derivatives and pharmaceutical compositions containing the same | |
IL175214A0 (en) | 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same |